Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Small bowel obstruction secondary to distal migration of the intestinal probe in...
Información de la revista
Vol. 41. Núm. 3.
Páginas 169-170 (Marzo 2018)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 41. Núm. 3.
Páginas 169-170 (Marzo 2018)
Scientific letter
DOI: 10.1016/j.gastrohep.2017.02.007
Acceso a texto completo
Small bowel obstruction secondary to distal migration of the intestinal probe in a patient with an endoscopic gastrostomy for continuous carbidopa-levodopa infusion
Obstrucción de intestino delgado secundaria a migración distal de la sonda intestinal en una paciente con gastrostomía endoscópica para la infusión continua de carbidopa-levodopa
Visitas
...
Arantxa Díaz Gómeza, Raquel Díaz Ruiza,
Autor para correspondencia
diaz.ruiz.r@gmail.com

Corresponding author.
, Óscar Nogalesa, Beatriz de la Casab, Carmen Fernández Alvárezc, Cecilia González Asanzaa
a Department of Gastroenterology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
b Department of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
c Department of Radiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Texto completo

Levodopa is the gold standard treatment for Parkinson's disease (PD). However, due to its short plasma half-life, requiring repeated doses, long-term levodopa use (usually within 5–10 years after initiating treatment) is associated with motor fluctuations and dyskinesias. Impaired gastric emptying is also common in PD patients and leads to unpredictable responses to oral medication. These facts induce disability and lower quality of life.1 Therapeutic alternatives for patients with advanced PD include deep brain stimulation, continuous subcutaneous apomorphine infusion and intrajejunal levodopa-carbidopa infusion. Continuous intraduodenal/intrajejeunal infusion of a levodopa-carbidopa (L-C) gel (Duodopa®, Abbvie) – which contains levodopa 20mg/ml plus carbidopa 5mg/ml – improves motor fluctuations2,3 (off time and severity and dyskinesia), non-motor symptoms,4 autonomy for basic activities5 and quality of life.6 This therapy is performed by placing a specific percutaneous endoscopic gastrostomy (PEG) kit (Frecka® PEG gastric set) that contains inside a 9Fr duodenal pigtail (Freka® CH9 intestinal tube) probe. This technique requires cooperation between the neurologist that sets the indication for this treatment and does a close surveillance of the patient, and the Gastroenterologist/Endoscopist that places the PEG probe and performs the surveillance and replacements of the device.

A 76 year-old woman with advanced PD complicated with motor fluctuations required Duodopa® administration to control her motor symptoms. Therefore, a PEG-Duodopa was placed, with Propofol sedation, after informing the patient and her family about the benefits and the possible risks related to the procedure. Thirty minutes before the PEG-duodopa allocation, the patient received antibiotic prophylaxis with Cefazolin 2g. It was performed without any immediate complications and lack of complications was verified by immediate endoscopic control, as usual. The patient was discharged from hospital 2 days after the procedure, with marked improvement of the motor symptoms, since PEG-duodopa was used for the first time 24h after its allocation. After eleven days, the patient was admitted to the emergency room because of abdominal distension with pain and vomiting, which was highly suggestive of an intestinal obstruction. Plain abdominal X-ray showed the duodenal probe tip of the Freka® CH9 Intestinal Tube projected in right iliac fossa and absence of pneumoperitoneum. Severe abdominal pain persisted despite administration of analgesics, so an urgent abdominal CT was indicated to discard any other complication. It confirmed the presence of the pigtail probe coiled in the ileum due to distal migration, conditioning severe retrograde small bowel dilation (Fig. 1). Since the patient had no response to conservative treatment, emergency surgery was indicated, performing an ileostomy, extraction of the probe and primary suture without associated complications. Ten days after surgery, after discussing the case between surgeons, endoscopists and neurologists, and with the agreement of the patient, placement of a new duodenal pigtail type probe was carried out without further complications.

Figure 1.

TC. Pigtail probe coiled in distal ileum due to migration, conditioning severe retrograde small bowel dilation.

(0,08MB).

Continuous L-C gel infusion is a highly effective and well accepted alternative for the treatment of advanced PD patients.5,6 Duodenal infusion avoids problems related to delayed stomach transit. It has a similar safety profile to oral medication providing better control of motor and non motor symptoms in those cases. However, specific complications related to probe placement cannot be overlooked. They include complications related to: (a) the stoma, like infection, granuloma development, etc., (b) the gastrostomy probe, like buried bumper syndrome; and (c) the pigtail probe: distal migration, bending, or probe break. Events that involve the probe are very frequent (a study7 described that more than 60% of the patients had at least 1 event with duodenal probe after one year with continuous L-C infusion). Distal migration is generally asymptomatic, with spontaneous anal expulsion. Perforation or intestinal obstruction8 secondary to probe migration as in the case exposed is exceptional.

References
[1]
S. Chapuis, L. Ouchchane, O. Metz, L. Gerbaud, F. Durif.
Impact of the motor complications of Parkinson's disease on the quality of life.
Mov Disord, 20 (2005), pp. 224-230
[2]
Hubert H. Fernandez, David G. Standaert, Robert A. Hauser, A.E. Lang, V.S. Fung, F. Klostermann, et al.
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Mov Disord, 30 (2015 Apr), pp. 500-509
[3]
C. Warren Olanow, Karl Kieburtz, Per Odin, et al.
Double-blind, double-dummy, randomized study of continuous intrajejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Lancet Neurol, 13 (2014), pp. 141-149
[4]
H. Honig, A. Antonini, P. Martínez-Martín, I. Forgacs, G.C. Faye, T. Fox, et al.
Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
Mov Disord, 24 (2009), pp. 1468-1474
[5]
A. Merola, A. Merola, M. Zibetti, S. Angrisano, L. Rizzi, M. Lanotte, et al.
Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease.
Mov Disord, 26 (2011), pp. 664-670
[6]
D. Santos-García, L.F. Sanjurjo, M. Macías, M. Llaneza, P. Carpintero, R. De la Fuente-Fernández.
Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being.
Acta Neurol Scand, 125 (2012), pp. 187-191
[7]
D. Nyholm, T. Lewander, A. Johansson, P.A. Lewitt, C. Lundqvist, S.M. Aquilonius.
Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
Clin Neuropharmacol, 31 (2008), pp. 63-73
[8]
M. Epstein, D.A. Johnson, R. Hawes, N. Schmulewitz, A.D. Vanagunas, E.R. Gossen, et al.
Long-term PEG-J tube safety in patients with advanced Parkinson's disease.
Clin Transl Gastroenterol, 7 (2016), pp. e159
Copyright © 2017. Elsevier España, S.L.U.. All rights reserved
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.